Skip to main content

Lung Cancer Field Targets Immunotherapy, Acquired Resistance, and Genomic Testing

*March 2022*

To build on the advances that have been made in lung cancer over the past several years, researchers have their sights set on improving the efficacy of immunotherapy with novel approaches, the ability to overcome acquired resistance to targeted therapies, and the accessibility to molecular testing and approved targeted therapies, said Suresh S. Ramalingam, MD, FACP, FASCO.

“We have seen substantial improvement in overall outcomes for patients with lung cancer in the past decade. There is an annual 2% to 4% decline in deaths related to lung cancer in the United States. Advances in treatments have been one of the major contributors to that. We’re making progress, and progress is coming by delivering personalized treatment approaches to patients based on biomarkers,” Ramalingam said in an interview with OncLive® following a State of the Science Summit™ on lung cancer.

In the interview, Ramalingam, executive director, Winship Cancer Institute of Emory University, professor and Roberto C. Goizueta Distinguished Chair for Cancer Research, Department of Hematology and Medical Oncology, Emory University School of Medicine, discussed current applications for frontline immunotherapy and targeted therapy for non–small cell lung cancer (NSCLC) and the current management of small cell lung cancer (SCLC). Read more.